FDA Warns Company Selling Misbranded Drugs With False Claims
The FDA issued a warning letter to NutraPharma, for selling false and misleading products that claim to treat addiction and chronic pain.
All articles by Steve Duffy
FDA to Review BLA for Oral Immunotherapy AR101 for Peanut Allergy
The Food and Drug Administration has accepted for review the Biologics License Application for AR101 (Aimmune Therapeutics) to reduce the risk of anaphylaxis following accidental exposure to peanut.
Clinical Outcomes Compared With Generics, Brand-Name Drugs for Chronic Conditions
An analysis found comparable clinical outcomes among patients who initiated generics vs those who were treated with brand-name drugs for chronic conditions.
FDA to Review Baloxavir Marboxil sNDA for Flu in Patients at High Risk for Complications
The FDA has accepted for review the sNDA for for Xofluza for the treatment of influenza in patients at high risk of complications.
Next post in Influenza
